THAR
Hillstream BioPharma Inc

3,125
Loading...
Loading...
News
all
press releases
Why Tharimmune (THAR) Shares Are Getting Hammered
Tharimmune shares are trading lower by 30% during Monday's session. The company late Friday announced it had entered into an 'at the market' offering agreement. read more...
Benzinga·1y ago
News Placeholder
More News
News Placeholder
Why Tharimmune (THAR) Shares Are Moving
Tharimmune shares are trading lower by 16.4% during Wednesday's session. The company announced a 1-for-15 reverse stock split. read more...
Benzinga·1y ago
News Placeholder
Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Decreases By 69.9%
Tharimmune, Inc. (NASDAQ:THAR Get Free Report) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 22,800 shares, a decrease of 69.9% from...
Ticker Report·1y ago
News Placeholder
Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now
MIAMI, March 06, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 68th Emerging Growth Conference on March 6 & 7, 2024. The...
Globe Newswire·2y ago
News Placeholder
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
Tharimmune invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth ConferenceBRIDGEWATER, NJ...
Accesswire·2y ago
News Placeholder
Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now
MIAMI, March 05, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 68th Emerging Growth Conference on March 6 & 7, 2024. The...
Globe Newswire·2y ago
News Placeholder
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous studiesPhase 1 clinical trial compared oral transmucosal delivery of...
Accesswire·2y ago
News Placeholder
Tharimmune doses first patient in Phase 1 trial of TH104
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104Phase 1 study expected to be completed in 1Q24 with...
Accesswire·2y ago
News Placeholder
Tharimmune provides update on TH-3215, TH-1940 non clinical-stage programs
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago

Latest THAR News

View

Advertisement. Remove ads.

Advertisement. Remove ads.